Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Aclaris takes a step towards an oral rheumatoid arthritis therapy.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
In terms of private investments, 2020 was the year of the liquid biopsy.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.